Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
Dorward, J.; Sookrajh, Y.; Lessells, R. J.; Bulo, E.; Bodley, N.; Singh, L.; Moodley, P.; Samsunder, N.; Drain, P. K.; Hayward, G.; Butler, C. C.; Garrett, N.
Show abstract
Limited data exists to inform management of viraemia among people receiving dolutegravir-based first-line ART in low- and middle-income countries. Among South-Africans with viraemia [≥]1000copies/mL receiving dolutegravir (n=43) and efavirenz (n=37), we found no dolutegravir resistance, but high efavirenz resistance (66.7%). 12-week resuppression was higher with dolutegravir (85%) versus efavirenz (38%).
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Temporal Trends And Transmission Dynamics Of Pre-Treatment HIV-1 Drug Resistance Within And Between Risk Groups In Kenya, 1986-2020 95%
- Notable transmitted HIV drug resistance among people who inject drugs in Pakistan 91%
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study 89%
Similar papers in this journal
- Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy 97%
- Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study 94%
- Field performance and cost-effectiveness of a point-of-care triage test for HIV virological failure in Southern Africa 94%
Similar papers in this journal
- Clinical outcomes after viraemia among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy in South Africa 97%
- Predictors of Clinical Outcomes among People with HIV and Tuberculosis Symptoms after Rapid Treatment Initiation in Haiti 95%
- Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification among Patients with Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-Income Countries 93%
Similar papers in this journal
- Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study 96%
- Risk of major adverse cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: emulated target trials using routine, de-identified data from South Africa 93%
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial 92%
Similar papers in this journal
- Time Between Viral Loads for People with HIV during the COVID-19 Pandemic 93%
- Differentiated HIV Service Delivery vs Conventional Care: Tuberculosis Preventive Therapy Outcomes for People Living with HIV in Sub-Saharan Africa 92%
- Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.